Literature DB >> 1391986

Why do so many prognostic factors fail to pan out?

S G Hilsenbeck1, G M Clark, W L McGuire.   

Abstract

Although there can be many reasons that one study fails to confirm the results of another, the consequences of data exploration and the potential for spuriously significant results are often overlooked. A series of simulation experiments were designed to mimic the characteristics of relapse-free survival data that might be encountered in a prognostic factor study of node-negative breast cancer patients. Each simulated dataset of 500 or 250 cases was divided into a training set, used to select the "best" prognostic factor cutpoint, and a validation set, used to confirm the cutpoint. Testing multiple cutpoints markedly increased the risk of making a Type I error. The power to detect even small true differences was substantial, and increased as the number of cutpoints increased. Regardless of the number of cutpoints tested on the training sets, the Type I error rate on an independent validation data set was quite stable and the power of the validation set to detect true differences was not related to the number of cutpoints. Validation power closely approximated that predicted for a simple two group comparison. It is therefore recommended that exploratory analyses of prognostic factors formally employ some method of adjusting for increased Type I errors, such as independent validation sets, ad hoc adjustment factors, or other statistical methods of estimating the true risk.

Entities:  

Mesh:

Year:  1992        PMID: 1391986     DOI: 10.1007/bf01840833

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Optimal mastectomy timing.

Authors:  W L McGuire; S Hilsenbeck; G M Clark
Journal:  J Natl Cancer Inst       Date:  1992-03-04       Impact factor: 13.506

2.  Breast cancer prognostic factors: evaluation guidelines.

Authors:  W L McGuire
Journal:  J Natl Cancer Inst       Date:  1991-02-06       Impact factor: 13.506

3.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

4.  CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors.

Authors:  U Abel; J Berger; H Wiebelt
Journal:  Methods Inf Med       Date:  1984-07       Impact factor: 2.176

5.  Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorisation of cut-off levels.

Authors:  H Sigurdsson; B Baldetorp; A Borg; M Dalberg; M Fernö; D Killander; H Olsson; J Ranstam
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

  5 in total
  31 in total

1.  Artificial intelligence for clinicians.

Authors:  P J Drew; J R Monson
Journal:  J R Soc Med       Date:  1999-03       Impact factor: 5.344

2.  Do commonly used clinical trial designs reflect clinical reality?

Authors:  Elihu Estey
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

3.  Nodal parameters of FDG PET/CT performed during radiotherapy for locally advanced mucosal primary head and neck squamous cell carcinoma can predict treatment outcomes: SUVmean and response rate are useful imaging biomarkers.

Authors:  Peter Lin; Myo Min; Mark Lee; Lois Holloway; Dion Forstner; Victoria Bray; Allan Fowler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-12-21       Impact factor: 9.236

Review 4.  Prognostic factors: rationale and methods of analysis and integration.

Authors:  G M Clark; S G Hilsenbeck; P M Ravdin; M De Laurentiis; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity.

Authors:  Ali M Allahdina; Paul F Stetson; Susan Vitale; Wai T Wong; Emily Y Chew; Fredrick L Ferris; Paul A Sieving; Catherine Cukras
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

6.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

Review 7.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

8.  Loss of blood group antigen A in non-small cell lung cancer.

Authors:  J L Gwin; A J Klein-Szanto; S Y Zhang; P Agarwal; A Rogatko; S M Keller
Journal:  Ann Surg Oncol       Date:  1994-09       Impact factor: 5.344

9.  Do we really need prognostic factors for breast cancer?

Authors:  G M Clark
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 10.  Applications and limitations of radiomics.

Authors:  Stephen S F Yip; Hugo J W L Aerts
Journal:  Phys Med Biol       Date:  2016-06-08       Impact factor: 3.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.